Talazoparib companion diagnostic - Myriad Genetics

Drug Profile

Talazoparib companion diagnostic - Myriad Genetics

Alternative Names: BMN-673 companion diagnostic; BRACAnalysis (Talazoparib); BRACAnalysis CDx (Talazoparib); Talazoparib - BRACAnalysis; Talazoparib - BRACAnalysis CDx

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Myriad Genetics
  • Developer BioMarin Pharmaceutical; Myriad Genetics
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 11 Apr 2017 Phase-III development for Breast cancer (Diagnosis) is ongoing in USA (unspecified)
  • 01 Oct 2013 Phase-III clinical trials in Breast cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top